Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quest Pharmatech Inc QPTFF


Primary Symbol: V.QPT

Healthcare Biotechnology
Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest... see more

Bullboard (TSXV:QPT)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
Comment by G1945Von Nov 19, 2020 7:04am

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

So the agreement in play is between two corporations having the same name.
73
Discussion
Comment by MrMugsyon Nov 18, 2020 7:16pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

I can only tell you that ... Since the deal was announced and since the IP has switched hands, Dual has decided to rename itself OncoQuest.
103
Discussion
Comment by G1945Von Nov 18, 2020 6:17pm

RE:RE:RE:RE:RE:RE:RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

So OncoQuest and Dual are one and the same company. Is there an agreement to explain this arrangement. I am totally confused.
54
Discussion
Comment by MrMugsyon Nov 18, 2020 5:39pm

RE:RE:RE:RE:RE:RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

Dual changed its name to OncoQuest in the past few months.  It should be the same thing.
91
Discussion
Comment by G1945Von Nov 18, 2020 5:09pm

RE:RE:RE:RE:RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

I find it strange that OncoQuest and Dual share prices are identical.  Market Summary > OncoQuest Pharmaceuticals Inc KOSDAQ: 078590 Follow  ...more  
86
Discussion
Comment by G1945Von Nov 18, 2020 4:30pm

RE:RE:RE:RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

To your point: "We have $125M purchased at 3806.3 - can acces $62.5M by yearend." The agreement reads as follows (below) when it comes to the 30 year bonds.(bolding added) It seems to ...more  
93
Discussion
Comment by MrMugsyon Nov 18, 2020 2:08pm

RE:RE:RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

The way I understand the deal, $62.5M can be liquidated by end of year. It is represented as a fixed number so I'm assuming it will not go higher if Dual (OncoQuest) shares go higher - as is the ...more  
80
Discussion
Comment by G1945Von Nov 18, 2020 10:59am

RE:RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

MrM.....How do you see this happening?. "Right now, I am betting we see some of that cash come our way in the form of a small divi." Thx G1945V
75
Discussion
Comment by MrMugsyon Nov 17, 2020 11:36pm

RE:RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

You are right PosNeg ... it should have. Huge disconnect between QPT and Oncoquest on the S. Korean Exchange. I've been scratching my head on this one for a few days. ----- Oncoquest is up 8.6 ...more  
95
Discussion
Comment by PosNeg1on Nov 16, 2020 12:01pm

RE:OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

This should have resulted in SP appreciation. However no one knows as zero IR activity.
92
Discussion
Post by G1945Von Nov 11, 2020 5:06pm

OncoQuest Pharmaceuticals Inc. Doses First Patient in Ph 3

November 9, 2020: Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline ...more  
407
Discussion
Post by MrMugsyon Nov 03, 2020 1:58pm

Placing my bet ... slowly accumulating

Very possible that we may see some of the funds come our way in the new year. Let's see what the company decides - if a special dividend comes out of this. Closely watching the exchange rate, our ...more  
120
Post by MrMugsyon Oct 08, 2020 1:26pm

OK ... slowly going back in

Gotta think the market isn't giving the deal any value. I'll go back in here for a bit. Let's call it a Christmas present to myself. Cheers!
74
Comment by ARIMA11on Oct 07, 2020 2:25pm

RE:RE:RE:RE:RE:FINANCIAL: Fiscal 2021+ MD&A

Oct 07 02:10:19 PM 0.105 155000   9 1 :)
91
Discussion
Comment by ARIMA11on Oct 07, 2020 2:10pm

RE:RE:RE:RE:FINANCIAL: Fiscal 2021+ MD&A

Oct 07 02:08:58 PM 0.11 20000   1 1 Oct 07 02:08:58 PM 0.11 20000   7 1  ...more  
76
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities